AKESO(HK:09926) Ge Long Hui·2025-12-07 10:36Core Insights - 康方生物's five approved drugs have been successfully included in the latest National Medical Insurance Drug List (2025) by the National Healthcare Security Administration of China, effective from January 1, 2026 [1][2][3] Group 1: Drug Approvals and Indications - 开坦尼 (卡度尼利, PD-1/CTLA-4) has renewed its existing indication for recurrent or metastatic cervical cancer and added new indications for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer, as well as first-line treatment for persistent, recurrent, or metastatic cervical cancer [1] - 依达方 (依沃西, PD-1/VEGF) has renewed its existing indication for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after progression on EGFR TKI treatment and added a new indication for first-line treatment of PD-L1 positive (TPS≥1%) locally advanced or metastatic NSCLC [1] - 安尼可 (派安普利, PD-1) is included for the treatment of second-line and above classical Hodgkin lymphoma, first-line locally advanced or metastatic squamous NSCLC, second-line or above nasopharyngeal carcinoma, and first-line nasopharyngeal carcinoma [2] - 伊喜宁 (伊努西, PCSK9) is included for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, as well as heterozygous familial hypercholesterolemia [2] - 爱达罗 (依若奇, IL-12/IL-23) is included for the treatment of moderate to severe plaque psoriasis [3] Group 2: Company Commitment and Future Plans - The company is dedicated to providing more globally innovative and best-in-class treatment options, continuously improving patient accessibility and affordability [3] - The company aims to deepen its focus in various disease areas and promote more innovative drugs and new indications to be included in the National Medical Insurance Drug List, benefiting more patients [3]